<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01752543</url>
  </required_header>
  <id_info>
    <org_study_id>H-3-2012-139</org_study_id>
    <nct_id>NCT01752543</nct_id>
  </id_info>
  <brief_title>Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients</brief_title>
  <official_title>Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Finn Gustafsson</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the present study is to evaluate the effects of a blockade of the vasopressin&#xD;
      system and central hemodynamic system in heart failure (HF) patients during physical&#xD;
      exercise. The significance of the vasopressin system during physical exercise is unclear. If&#xD;
      vasopressin is a significant regulator of exercise hemodynamics in HF, strategies to&#xD;
      intervene against activation of the V1A-receptor might be expected to improve HF symptoms and&#xD;
      possibly outcome.&#xD;
&#xD;
      The potential effects of the central hemodynamic system will be evaluated with a Swan-Ganz&#xD;
      catheter. Echocardiography will be performed at rest and during submaximal working capacity&#xD;
      before and during the infusion of a vasopressin receptor antagonist (conivaptan) or placebo.&#xD;
      Cardiac output will be measured by thermodilution. The exercise test will be performed at 50&#xD;
      % of VO2 max and hemodynamic and echocardiographic measurements will be collected. The&#xD;
      exercise test will be performed on a supine multistage bicycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The joint endpoint of change in pulmonary capillary wedge pressure (PCWP) and cardiac output (CO) at the submaximal exercise intensity of 50 % of the maximal exercise capacity</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac index (CI) during submaximal exercise from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary and systemic vascular resistance from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end diastolic diameter during exercise from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in mean pulmonary artery pressure (mPAP) from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in BNP, MR-ANP and copeptin from rest to submaximal exercise</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Conivaptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 patients will be randomized to conivaptan treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dextrose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 patients will receive placebo treatment (dextrose)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conivaptan</intervention_name>
    <description>Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour</description>
    <arm_group_label>Conivaptan</arm_group_label>
    <other_name>Vaprisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Dextrose)</intervention_name>
    <description>Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour</description>
    <arm_group_label>Dextrose</arm_group_label>
    <other_name>5 % dextrose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &lt; 45 % on the baseline echocardiography.&#xD;
&#xD;
          -  Treatment with beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors for at&#xD;
             least 1 month as tolerated&#xD;
&#xD;
          -  New York Heart Association (NYHA) Functional Class II-III&#xD;
&#xD;
          -  Given informed consent&#xD;
&#xD;
          -  Women, who have not yet entered menopause (defined as no menstrual bleeding in the&#xD;
             last 12 months), will provide a negative urine HCG before entering the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs of symptomatic or ongoing myocardial ischemia&#xD;
&#xD;
          -  Known non-revascularized coronary disease&#xD;
&#xD;
          -  Presence of hypovolemic hyponatremia (P-Na+ &lt;130 mmol/l and clinical signs of volume&#xD;
             depletion or dehydration as judged by investigator).&#xD;
&#xD;
          -  Hypernatraemia (P-Na+) &gt; 145 mmol/L&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease (FEV1/FVC &lt; 70 % and/or 30 % &gt; FEV1 &lt; 50 %)&#xD;
&#xD;
          -  Supine systolic blood pressure &lt; 85 mmHg&#xD;
&#xD;
          -  Significant orthostatic hypotension&#xD;
&#xD;
          -  Standing blood pressure &lt; 80 mmHg or a blood pressure drop &gt; 20 mmHg when changing&#xD;
             from a supine to a standing position&#xD;
&#xD;
          -  Uncontrolled hypertension evaluated by the investigator&#xD;
&#xD;
          -  Uncontrolled cardiac arrhythmias evaluated by the investigator&#xD;
&#xD;
          -  Untreated serious hypothyroidism&#xD;
&#xD;
          -  Adrenal insufficiency&#xD;
&#xD;
          -  Poor echocardiographic window&#xD;
&#xD;
          -  Inability to perform exercise testing&#xD;
&#xD;
          -  Permanent atrial fibrillation or atrial fluttering&#xD;
&#xD;
          -  Planned coronary by-pass surgery&#xD;
&#xD;
          -  Moderate hepatic impairment (ALAT/ASAT &gt; 3 UNL)&#xD;
&#xD;
          -  Presence of other diseases affecting treatment with conivaptan or the evaluation of&#xD;
             safety as evaluated by the investigator&#xD;
&#xD;
          -  Severely decreased kidney function (eGFR &lt; 20 mL/min)&#xD;
&#xD;
          -  Serum K+&lt; 3.5 or &gt; 5.5 mmol/L&#xD;
&#xD;
          -  Known conivaptan intolerability&#xD;
&#xD;
          -  Corn allergy&#xD;
&#xD;
          -  Dextrose Allergy&#xD;
&#xD;
          -  Treatment with potent CYP3A-inhibitors (ketoconazole, itraconazole, clarithromycin,&#xD;
             ritonavir, indinavir)&#xD;
&#xD;
          -  Treatment with arginine vasopressin, oxytocin, desmopressin and other medications for&#xD;
             the treatment of hyponatremia (lithium salts, urea and demeclocycline)&#xD;
&#xD;
          -  Warfarin treatment&#xD;
&#xD;
          -  Presence of infection or active bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise Balling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Finn Gustafsson, MD, PhD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Copenhagen University Hospital, Rigshospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>December 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2012</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Finn Gustafsson</investigator_full_name>
    <investigator_title>Staff Cardiologist, MD, Phd, DMSci</investigator_title>
  </responsible_party>
  <keyword>Vasopressin</keyword>
  <keyword>Exercise capacity</keyword>
  <keyword>Conivaptan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conivaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

